Oxford BioDynamicsLSE:OBD -21.51% Gross Margin % is 42.52% as of Sep. 2025, which is 12% below its 10-year median of 48.40. The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 52.58% on this metric.
The historical rank and industry rank for Oxford BioDynamics's Gross Margin % or its related term are showing as below:
LSE:OBD'
s Gross Margin % Range Over the Past 10 Years
Min: -36.4 Med: 48.4 Max: 75.32
Current: 47.67
During the past 13 years, the highestGross Margin % of Oxford BioDynamics was 75.32%. The lowest was -36.40%. And the median was 48.40%.
LSE:OBD's Gross Margin % is ranked worse than 52.58% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs LSE:OBD: 47.67
Oxford BioDynamics had a gross margin of 42.52% for the quarter that ended in Sep. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Oxford BioDynamics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Oxford BioDynamics had a gross margin of 42.52% for the quarter that ended in Sep. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Oxford BioDynamics Gross Margin % Related Terms
Oxford BioDynamics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OBD vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Oxford BioDynamics (LSE:OBD) has a Gross Margin % of 42.52% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Oxford BioDynamics and its competitors. This is 12% below median its historical median of 48.40. According to the industry distribution chart, Oxford BioDynamics ranks #102 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Oxford BioDynamics' Gross Margin % too high?
Oxford BioDynamics' current Gross Margin % of 42.52% is 12% below median its 10-year median of 48.40. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. Oxford BioDynamics' value of 42.52% is 15.7% below this industry median. Based on the distribution chart, Oxford BioDynamics ranks #102 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Oxford BioDynamics' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #102 out of 194 companies for Gross Margin %. This places Oxford BioDynamics in the lower half of its industry. The industry median Gross Margin % is 50.45. Oxford BioDynamics' value of 42.52% is 15.7% below this benchmark. While the company's 10-year median is 48.40 vs. the industry median of 50.45, Oxford BioDynamics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioDynamics's current Gross Margin % of 42.52% is 15.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Oxford BioDynamics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioDynamics's current Gross Margin % is 42.52%, which is 12% below median its own 10-year median of 48.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (LSE:OBD) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 93.3% below its estimated fair value. The current Gross Margin % is 42.52%, which is 12% below median its 10-year median of 48.40 and 15.7% below the Medical Diagnostics & Research industry median of 50.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Oxford BioDynamics (LSE:OBD), the current Gross Margin % is 42.52% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OBD has been successfully added to your 